Onderzoeker
Jan Sadones
- Trefwoorden:Geneeskunde
Affiliaties
- Anatomo-pathologie (Departement)
Lid
Vanaf4 jan 2010 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf22 jun 2017 → 7 sep 2017 - Ondersteunende Klinische wetenschappen (Departement)
Lid
Vanaf1 dec 2016 → 31 dec 2018 - Pathologische Anatomie (Departement)
Lid
Vanaf4 jan 2011 → 31 jan 2012 - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 okt 2003 → 31 dec 2009
Publicaties
1 - 10 van 10
- Potential of UCHL1 as biomarker for destruction of pancreatic beta cells(2015)
Auteurs: Benedicte Brackeva, Veerle De Punt, Gertjan Kramer, Olivier Costa, Katrijn Verhaeghen, Geert Stangé, Jan Sadones, Catarina Xavier, Jelle Aerts, Frans K Gorus, et al.
Pagina's: 156-167 - miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells(2013)
Auteurs: Gang Chen, Ijeoma Umelo, Shasha Lv, Erik Teugels, Karel Fostier, Peter Kronenberger, Alex Dewaele, Jan Sadones, Caroline Geers, Jacques De Grève
- Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab(2012)
Auteurs: Shasha Lv, Erik Teugels, Jan Sadones, Sylvia De Brakeleer, Johnny Duerinck, Stephanie Du Four, Alex Michotte, Jacques De Grève, Bart Neyns
Pagina's: 1029-1035 - Correlation between IDH1 Gene Mutation Status and Survival of Patients Treated for Recurrent Glioma(2011)
Auteurs: Shasha Lv, Erik Teugels, Jan Sadones, Erik Quartier, Mike Huylebrouck, Stephanie Du Four, Marie Le Mercier, O. De Witte, Isabelle J Salmon, Alex Michotte, et al.
Pagina's: 4457-4463 - Phase II study of sunitinib malate in patients with recurrent high-grade glioma(2011)
Auteurs: Bart Neyns, Jan Sadones, C. Chaskis, Martine Dujardin, Hendrik Everaert, Shasha Lv, Johnny Duerinck, O Tynninen, N Nupponen, Alex Michotte, et al.
Pagina's: 491-501 - Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma;(2009)
Auteurs: Bart Neyns, Jan Sadones, Eric Joosens, F Bouttens, L Verbeke, Jean-François Baurain, L Dhondt, T Strauven, C. Chaskis, Pieter in 't Veld, et al.
Pagina's: 1596-1603 - MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma(2009)
Auteurs: Jan Sadones, Alex Michotte, Pieter in 't Veld, C. Chaskis, R. Sciot, J Menten, E.j.r. Joossens, T Strauven, L.a. D'hondt, D. Sartenaer, et al.
Pagina's: 146-153 - A MULTICENTER STRATIFIED PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA(2008)
Auteurs: Bart Neyns, Jan Sadones, E.j.r. Joossens, F Bouttens, L Verbeke, J. Baurain, Lionel D'hondt, T Strauven, C. Chaskis, Alex Michotte
Pagina's: 1067-1067 - A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma(2008)
Auteurs: Bart Neyns, C. Chaskis, Eric Joosens, Johan Menten, Lionel D'hondt, Fabrice Branle, Jan Sadones, Alex Michotte
Pagina's: 269-277 - PRIMARY LEPTOMENINGEAL ANAPLASTIC OLIGODENDROGLIOMA WITH A 1P36-19Q13 DELETION: REPORT OF A UNIQUE CASE SUCCESSFULLY TREATED WITH TEMOZOLOMIDE(2008)
Auteurs: Alex Michotte, C. Chaskis, Bart Neyns, A. Tyberghien, M Declerck, Ines Origer, Jan Sadones, Pieter in 't Veld
Pagina's: 1087-1088